Rafael Medrano, who is the General Director of the Oncological Hospital of the National Medical Center (CMN) Siglo XXI at IMSS, participated in the High-Level Forum on Public Policies regarding triple-negative breast cancer (TNBC) in Mexico. The event took place at the National Academy of Medicine.
At the forum, Dr. Medrano emphasized the importance of working together with hospitals and institutions to develop policies that benefit women affected by triple-negative breast cancer. He highlighted the need to implement effective public policies and promote early detection of this disease.
Breast cancer is the most common malignant neoplasm among women, and in IMSS, the incidence of triple-negative cancer reaches 16.5%, according to Dr. Medrano. In this regard, he underlined the importance of ensuring that patients receive the best therapeutic options in a timely manner once cancer is detected.
Dr. Medrano also mentioned the instructions from the director of IMSS, Zoé Robledo, regarding the need to ensure quality and timely medical care, especially in the case of triple-negative cancer. The forum brought together prominent researchers and health professionals, promoting the exchange of ideas and discussions on public policies related to this disease.
During an exclusive interview for Oncologia.mx, Rafael Medrano Guzmán highlighted the seriousness of triple-negative breast cancer as a significant public health issue. The Director of the Oncological Hospital of CMN Siglo XXI expressed his confidence that the forum participants would acquire valuable knowledge and relevant conclusions for the fight against this disease.
At the event, thanks were given to the National Academy of Medicine and its president, Carrillo Esper, for organizing this important meeting and for highlighting the importance of collaboration in the fight against triple-negative breast cancer. The conclusions and discussions from the forum aim to contribute to better health management and public policies for the benefit of women affected by this disease.
